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Abstract
Persistent exposure of the immune system to death cell debris leads to autoantibodies
against chromatin in patients with systemic lupus erythematosus (SLE). Deposition of anti-
chromatin/chromatin complexes can instigate inflammation in multiple organs including the
kidney. Previously we identified specific cell death-associated histone modifications as tar-
gets of autoantibodies in SLE. In this study we addressed, in a large cohort of SLE patients
and controls, the question whether plasma reactivities with specific histone peptides asso-
ciated with serology and clinical features. Plasma from SLE patients with and without lupus
nephritis, disease controls, and healthy controls, were tested in ELISA with histone H4 pep-
tide acetylated at lysines 8, 12 and 16 (H4pac), H2B peptide acetylated at lysine 12
(H2Bpac), H3 peptide trimethylated at lysine 27 (H3pme), and their unmodified equivalents.
SLE patients displayed a higher reactivity with the modified equivalent of each peptide.
Reactivity with H4pac showed both a high sensitivity (89%) and specificity (91%) for SLE,
while H2Bpac exhibited a high specificity (96%) but lower sensitivity (69%). Reactivity with
H3pme appeared not specific for SLE. Anti-H4pac and anti-H2Bpac reactivity demonstrated
a high correlation with disease activity. Moreover, patients reacting with multiple modified
histone peptides exhibited higher SLEDAI and lower C3 levels. SLE patients with renal
involvement showed higher reactivity with H2B/H2Bpac and a more pronounced reactivity
with the modified equivalent of H3pme and H2Bpac. In conclusion, reactivity with H4pac and
H2Bpac is specific for SLE patients and correlates with disease activity, whereas reactivity
with H2Bpac is in particular associated with lupus nephritis.
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Introduction
Autoantibodies in patients with SLE are directed against numerous nuclear constituents
including chromatin [1–2], for which the basic structure consists of DNA wrapped around a
core of histone proteins H2A, H2B, H3 and H4. Approximately 40% of the SLE patients
develop lupus nephritis, where inflammation occurs in the filtration units of the kidney, i.e. the
glomeruli, due to the deposition of chromatin/anti-chromatin complexes [2,3]. Instigation of
the anti-chromatin response in SLE is explained by an insufficient removal of cells undergoing
programmed cell death (apoptosis) or neutrophil extracellular trap formation (NETosis) [4,5].
This leads to the persistent presence of chromatin-containing material derived from death cells
as we have recently shown in SLE patients [6]. The immunostimulatory properties of death
cell-derived chromatin are enhanced by apoptosis-related post-translational modifications
(PTMs) of the N-terminal tails of histones [7]. Characterization of the epitopes of monoclonal
autoantibodies derived from lupus mice previously led to the identification of several apopto-
sis-associated histone modifications, including histone H4 acetylation at lysines 8, 12 and 16
[8], H2B acetylation at lysine 12 [9], and H3 trimethylation at lysine 27 [10]. The identified his-
tone modifications are also present in non-apoptotic cells, where these have been linked to pro-
cesses such as the regulation of gene expression. However, we have previously shown that the
amount of these modifications hugely increases when cells go into apoptosis or NETosis [8–
11]. Importantly, autoantibodies in plasma samples of murine lupus models and SLE patients
recognizedhistone peptides with these identified PTMs more avidly compared to the corre-
sponding unmodifiedpeptides [8–10]. In addition, circulating apoptotic particles in SLE
patients contain chromatin with these apoptosis-associated histone modifications [6]. Recently,
we have shown that these histone modifications are also increased in neutrophil extracellular
traps (NETs) [11]. SLE plasma also contain autoantibodies that recognize several additional
types of chromatin PTMs, like peroxynitrite-treatedH2A [12], isomerizedH2B [13], and con-
formational acetylated epitopes [14].
Peptides displaying PTMs are powerful tools for the diagnosis of autoimmune diseases in
which post-translationally modified autoantigens play a pathogenic role [15]. Assays using
peptides that contain citrulline (deiminated arginine residues) are highly predictive and spe-
cific for the diagnosis of rheumatoid arthritis [16]. Recently, two distinct subfamilies of anti-
citrulline antibodies against citrullinated fibrin-derivedpeptides were identified [17]. In addi-
tion, two citrullinated histone H4 peptides were shown to be preferentially recognizedby auto-
antibodies present in the majority of patients with rheumatoid arthritis, but not in SLE [18].
Another example is the use of N-glycosylated peptides as an antigenic biomarker for patients
with multiple sclerosis [19]. The aforementioned studies also suggest that reactivity to specific
modified epitopes can be related to different autoimmune diseasemanifestations. With regard
to SLE, the diagnostic potential of peptides that contain PTMs remains rather elusive at pres-
ent. Total chromatin and/or dsDNA are the primary antigens employed in diagnostic assays,
including ELISA, and Farr and Crithidia assays, while histones are used to a lesser extent. In
the past, several histone peptides comprised of different, mostly N-terminal, regions of histones
have been identified as targets for autoantibodies in SLE patients, but these studies did not
include modified residues [20–21]. Although, assays to detect antibodies against chromatin or
dsDNA in SLE display a relatively high specificity and sensitivity, in particular in patients with
lupus nephritis [2,22–23], they also have some drawbacks. The exact composition of the chro-
matin in the assay largely depends on the source used for isolation, and chromatin modifica-
tions obviously vary extensively between different cells or tissues. This might explain why
different studies reported a high variability in specificity and sensitivity when using different
anti-dsDNA and anti-chromatin assays [2, 23]. More importantly, in these cases chromatin/
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dsDNA was isolated from sources that mostly consist of healthy, non-apoptotic cells. There-
fore, the isolated chromatin will not possess the same type and amount of PTMs compared to
chromatin derived from apoptotic cells. Therefore, the antigens normally used in the assay do
not represent the actualautoantigens responsible for the induction of the autoimmune response
in SLE patients. Two recent studies, that used advanced microarray-based assays, have under-
lined the potential impact of modifiedhistone peptides for the diagnosis of SLE [24–25]. These
studies compared the reactivity of sera from a selected group of SLE patients with a range of
different modified and unmodifiedhistone peptides. An enhanced reactivity was observedwith
several modifiedhistone peptides compared to the corresponding peptides without the modifi-
cations. Importantly, the modificationswe previously linked to SLE, i.e. histone H4 peptides
acetylated at lysines 8, 12 and 16, H3 peptides trimethylated at lysine 27 and H2B acetylated at
lysine 12 were among the prime targets for SLE autoantibodies as reported by aforementioned
studies. The highest reactivity was found in SLE patients with a prominent IFN-signature,
which is associated with higher disease activity [24].
In this study we measured the reactivity with our previously identified apoptosis modified
histone peptides in a large cohort of SLE patients with and without nephritis, disease controls
and healthy controls, and evaluated the correlation with serology and clinical parameters.
Methods
Patients
Cross-sectional plasma from 102 SLE patients with active, biopsy-proven proliferative lupus
nephritis (formerly known as WHO class III, IV, Vc or Vd), 76 SLE patients without nephritis,
consecutive sera from 15 SLE patients experiencing disease flares, as well as plasmas from 12
patients with rheumatoid arthritis (RA) and 12 patients with systemic sclerosis (SSc) were col-
lected at the RadboudUniversity Medical Center, the RheumatologyClinic at Linköping Uni-
versity Hospital, and the University Hospital Erlangen. Plasma samples were taken at the time
of diagnosis. The majority of patients were Caucasian and female, and all patients with SLE ful-
filled4 American College of Rheumatology (ACR) criteria [26]. Disease activity was mea-
sured with total SLE disease activity index (SLEDAI) [27], or SLEDAI-2K [28]. Healthy
controls used in this study were age- and gender matched. Oral and written informed consent
was obtained from all subjects. The study protocol was approved by the Linköping University
Ethical ReviewBoard, Sweden; by the RadboudUniversity Medical Centre Ethical Review
Board, the Netherlands; and by the University Hospital Erlangen Ethical ReviewBoard,
Germany.
ELISA and Other Immunoassays
Peptides used for coating were either synthesized using in-house facilities in Strasbourg or
obtained commercially (Abcam, Cambridge, U.K.) and are listed in Table 1. Two μM of peptide
was coated overnight, blocked with 5% fetal calf serum (FCS) in PBS, incubated for 2 hours
with plasma diluted 1:50 and 1:100, and subsequently incubated for 1 hour with horseradish
peroxidase (HRP)–conjugated goat anti-human IgG(H+L) diluted 1:10,000 (Southern Biotech-
nology, Birmingham, U.S.A.), as previously described.[5]Each patients’ plasma was tested with
all peptides in the same experiment. Reactivity with each peptide was calculated as OD
(450nm) x dilution. Cut-off values were determined as 3x background signal (without plasma)
and were set at 12.6 (H4p), 12.7 (H4pac), 11.7 (H2Bp), 14.7 (H2Bpac), 14.9 (H3p) and 16.9
(H3pme). Peptide coating was checked by incubation with the appropriate lupus mouse-derived
monoclonal antibodies (KM-2, LG11-2, or BT164) [8–10]. Anti-histone, -dsDNA,–chromatin,
and –C1q ELISAs were performed as previously described [29]. Briefly, for the anti-dsDNA
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ELISA, calf thymus dsDNA (Roche, Almere, The Netherlands) was coated overnight in phos-
phate-buffered saline (20 mg/ml). The anti-nucleosome ELISA, was performed using calf thy-
mus H1-stripped chromatin (kindly provided by Dr R Burlingame, INOVA Diagnostics Inc,
San Diego, California, USA), diluted in phosphate-buffered saline (5 mg/ml). In the anti-his-
tone ELISA, calf thymus total histones (containing histones H1, 2A, 2B, 3 and 4; Roche) were
coated overnight (2.5 mg/ml) in 0.1 M glycine buffer at pH 9. Rest of the assay was performed
as described above for peptides. For the anti-C1q ELISA, plates were coated overnight with 3 g/
well plasma-derived C1q in bicarbonate buffer pH 9.6. Calf thymus-derived chromatin and
total histones tested positive for monoclonal antibodies against non-modified and modified
histones [8–10]. Measurements of anti-dsDNA antibodies in Crithidia and Farr assays were
performed according to local standards, as previously described [30,31].
Statistics
Statistical analysis was performed using SPSS (Chicago, Illinois, U.S.A.) and Graphpad Prism
(San Diego, California, U.S.A.). The one-way ANOVA test was used for comparison of the
reactivity betweenmultiple groups (Figs 1 and 2B, and S2 Table), and p values were corrected
using the Bonferroni’s Multiple Comparison Test. ROC curveswere compared using the
Delong method. In addition, the Mann-Whitney U test was used for comparison of two indi-
vidual groups (Fig 2A), and theWilcoxon signed rank test was used to compare sets of ordinal
data (S2 Table). Spearman’s rank correlation coefficientwas used to compare correlations. P
values<0.05 were regarded as significant, unless stated otherwise.
Results
Reactivity with H4pac and H2Bpac Is Specific for SLE patients, whereas
H2Bpac Reactivity Is Particularly Associated with Lupus Nephritis
A cohort of 178 patients with SLE was tested in ELISA for reactivity with H4pac, H2Bpac and
H3pme, along with their unmodifiedequivalents (Table 1). The percentage of positive SLE
patients was highest for H4pac and H3pme, followed by H4p, H2pac and H2Bp, and lowest for
H3p (Fig 1). Overall, SLE patients demonstrated a significantly higher reactivity with the modi-
fied histone peptide, as compared with the unmodifiedequivalent.Within the cohort, enhanced
reactivity with the modified equivalent was observed in 84%, 58% and 83% of the patients for
H4pac, H2Bac and H3pme, respectively. SLE patients showed a significantly higher reactivity
with H4p, H4pac, H2Bp and H2Bpac, compared to patients with other autoimmune disease (RA
or SSc), and healthy subjects (Fig 1). For H3p, no significant difference was observed,while
H3pme reactivity was only significantly higher compared to patients with other autoimmune
Table 1. Histone peptides used in this study.
Abbreviation1 Peptide Sequence
H4p H41-22 SGRGKGGKGLGKGGAKRHRKVL
H4pac H41-22-K8,12,16ac SGRGKGGK(Ac)GLGK(Ac)GGAK(Ac)RHRKVL
H2Bp H2B1-18 PDPAKSAPAPKKGSKKAV
H2Bpac H2B1-18-K12ac PDPAKSAPAPKK(Ac)GSKKAV
H3p H318-37 KQLATKVARKSAPATGGVKK
H3pme H321-34-K27me3 ATKVARK(me3)SAPATGG
1H4p, histone H4 peptide; H4pac, histone H4 peptide acetylated at lysine 8, 12 and 16; H2Bp, histone H2B peptide; H2Bpac, histone H2B peptide acetylated
at lysine 12; H3p, histone H3 peptide; H3pme, histone H3 peptide trimethylated at lysine 27
doi:10.1371/journal.pone.0165373.t001
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diseases. In fact, patients with RA or SSc tested only occasionally positive for H4P (3/24), H4pac
(3/24), H2Bp (0/24), or H2Bpac (2/24), while a considerable number of these patients tested pos-
itive for H3p (11/24) and H3pme (15/24). Higher reactivity of RA/SScplasmaswith modified
peptides was sporadically found for H4pac and H2Bpac (1/24 and 2/24 respectively), but more
frequently for H3pme (9/24). There was no significant difference betweenRA and SSc patients.
Overall the reactivity with modifiedpeptides was not significantly different from that with the
unmodifiedequivalents for RA and SSc. Samples of healthy subjects also tested occasionally pos-
itive for H4P, H4pac, H2Bp or H2Bpac, but the reactivity was always rather low (<20 AU, Fig 1)
and no superior reactivity with modifiedpeptides was found. Surprisingly, we found that the
majority of healthy controls tested positive for H3p and H3pme.
Within the cohort of SLE patients, patients with and without lupus nephritis were compared
(Fig 2). For H4p and H4pac, a higher percentage of positives in patients with lupus nephritis
Fig 1. Reactivity with histone peptides containing apoptosis-associated modifications and their unmodified
counterparts. Plasma samples from SLE patients were tested in ELISA with the indicated modified histone peptides and
their unmodified counterparts (i.e. H4p, H2Bp, and H3p). Patients with rheumatoid arthritis (RA) or systemic sclerosis
(SSc), and healthy individuals were used as controls. * p<0.01 compared to the unmodified equivalent as determined
using the Mann-Whitney U test; # p<0.01 compared to healthy subjects and patients with other autoimmune diseases and
^ p<0.01 compared to patients with other autoimmune diseases using the one-way ANOVA test. H4p, histone H4 peptide;
H4pac, histone H4 peptide acetylated at lysine 8, 12 and 16; H2Bp, histone H2B peptide; H2Bpac, histone H2B peptide
acetylated at lysine 12; H3p, histone H3 peptide; H3pme, histone H3 peptide trimethylated at lysine 27.
doi:10.1371/journal.pone.0165373.g001
Reactivity against Modified Histone Peptides in SLE
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Fig 2. Reactivity with histone peptides containing apoptosis-associated modifications and with their
unmodified counterparts in SLE patients with and without lupus nephritis. (A) Plasma samples from
SLE patients with or without nephritis were tested in ELISA with the indicated modified histone peptides and
their unmodified counterparts (i.e. H4p, H2Bp, and H3p). (B) Ratio of the reactivity with the respective
modified histone peptide divided by the reactivity with the unmodified counterpart, for SLE patients with and
without nephritis. In all cases the one-way ANOVA test was used for statistical comparison. * p<0.001. H4p,
Reactivity against Modified Histone Peptides in SLE
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was observed,while the median reactivity (Fig 2a) and modified/unmodifiedratio (Fig 2b) was
similar between both groups. For H2p and H2pac SLE patients without lupus nephritis exhib-
ited a lower percentage of positives, a lower median reactivity and a lower modified/unmodi-
fied ratio. In addition, patients without lupus nephritis showed a lower reactivity with H3p, a
higher reactivity with H3pme, and as a consequence a higher ratio of H3pme/H3p. For 49% of
the SLE patients with lupus nephritis, versus 28% for patients without lupus nephritis, an
enhanced reactivity with the modified equivalent for all three modifiedhistone peptides was
observed. In addition, the majority of patients with lupus nephritis tested positive for three
modifiedpeptides (75%), while 20% tested positive for 2 modifiedpeptides, 3% for 1 modified
peptide, and only 2% was negative for all of the modified peptides. Patients that tested negative
for H4pac, also tested negative for H2Bpac, while only part of those patients were negative for
H3pme. For patients without lupus nephritis, 35%, 46% and 11% tested positive for three, two
and one modifiedpeptide, respectively.
Sensitivity and specificitywere determined for each of the tested histone peptides (Table 2),
and receiver operator characteristics (ROC) curveswere calculated (Fig 3). In all cases the sen-
sitivity for the modifiedpeptide was higher compared to the unmodified equivalent, which was
also reflected in the ROC curves (Fig 3a–3c). As shown in Table 2, H4pac showed a very high
sensitivity (88.8%) and specificity (91.3%, compared to all controls), while H2Bpac showed a
high specificity (95.7%) but lower sensitivity (69.1%) and H3pme showed a high sensitivity
(87.6%) but very low specificity (20.0%). H4pac appeared to be the best performer in identifying
SLE patients when compared to all controls or healthy controls (Fig 3a and 3c), followed by
H2Bpac, while differences were smaller when SLE patients were only compared to disease con-
trols (Fig 3b). Specificity for H4pac and H2Bpac was similar when compared to healthy controls
and disease controls (Table 2). Combining reactivity with different modifiedpeptides did not
significantly improve sensitivity and/or specificity. Sensitivity for all peptides, and in particular
for H4p/H4pac and H2Bp/H2Bpac significantly increasedwhen only SLE patients with lupus
nephritis were included in the calculations. Finally, the specificity for H4pac and H2Bpac of
patients with lupus nephritis versus all controls including SLE patients without lupus nephritis,
histone H4 peptide; H4pac, histone H4 peptide acetylated at lysine 8, 12 and 16; H2Bp, histone H2B peptide;
H2Bpac, histone H2B peptide acetylated at lysine 12; H3p, histone H3 peptide; H3pme, histone H3 peptide
trimethylated at lysine 27.
doi:10.1371/journal.pone.0165373.g002
Table 2. Specificity and sensitivity of (modified) histone peptide ELISAs in SLE patients.
SLE Lupus
nephritis
SLE vs. all
controls
SLE vs. healthy
controls
SLE vs. disease
controls
Lupus nephritis vs. all controls
incl. SLE w/o nephritis
Peptide1 Sensitivity (%) Sensitivity (%) Specificity (%) Specificity (%) Specificity (%) Specificity (%)
H4pac 88.8 95.0 91.3 87.5 95.5 46.7
H4p 49.4 78.2 87.0 87.5 86.4 55.7
H2Bpac 69.1 77.4 95.7 91.7 100 67.2
H2Bp 63.4 80.4 91.3 100 77.3 63.1
H3pme 87.6 92.2 20.0 37.5 4.6 19.7
H3p 43.8 55.9 58.7 58.3 19.1 67.2
H4pac or H2Bpac 90.4 95.0 87.0 79.2 95.5 42.6
H4pac and H2Bpac 66.3 85.2 100 100 100 74.6
1H4p, histone H4 peptide; H4pac, histone H4 peptide acetylated at lysine 8, 12 and 16; H2Bp, histone H2B peptide; H2Bpac, histone H2B peptide acetylated
at lysine 12; H3p, histone H3 peptide; H3pme, histone H3 peptide trimethylated at lysine 27
doi:10.1371/journal.pone.0165373.t002
Reactivity against Modified Histone Peptides in SLE
PLOS ONE | DOI:10.1371/journal.pone.0165373 October 25, 2016 7 / 16
was 46.7% and 67.2%, respectively. ROC curves in Fig 3d and 3e confirmed that comparing
SLE patients, including patients with nephritis, with healthy controls and RA/SSc patients
resulted in a high area under the curve for H4pac and H2Bpac, while a lower area under the
curvewas observedwhen lupus nephritis patients were compared with all controls including
SLE patients without nephritis.
Reactivity with H4pac and H2Bpac Correlates with Disease Activity in
SLE Patients
The correlation of reactivities with different peptides, other nucleosomal antigens, and several
relevant clinical parameters was determined for SLE patients with lupus nephritis. The
Fig 3. H4pac appears superior in distinguishing SLE patients from healthy and disease controls. ROC curves for (modified)
histone peptide ELISAs were calculated for SLE vs. all controls (A), SLE vs. healthy controls (B), SLE vs. disease controls (C),
lupus nephritis vs. all controls (not including SLE without nephritis) (D), and lupus nephritis vs. all controls including SLE without
nephritis (E). *, p<0.05 vs. unmodified; #, p<0.01 vs. H2Bpac; ^, p<0.01 vs. H3pme.
doi:10.1371/journal.pone.0165373.g003
Reactivity against Modified Histone Peptides in SLE
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reactivity towards each modifiedpeptide highly correlated with the reactivity against the
unmodified equivalent (Table 3). For 61 patients the reactivity in ELISA with dsDNA, chroma-
tin, histones, and C1q; and the reactivity with anti-dsDNA antibodies in routine diagnostic
assays (Farr and Crithidia assay) were measured. Anti-H4pac, anti-H2Bpac and anti-H2Bp
reactivity was highly correlated with anti-dsDNA and anti-chromatin reactivity, while reactiv-
ity with H4p, H3pme or H3p showed a low correlation with anti-dsDNA and no correlation
with anti-chromatin reactivity. Only the reactivity with H2Bp, H2Bpac and H3p significantly
correlated with anti-histone reactivity. Anti-H2Bpac, H2Bp and H3p showed a significant cor-
relation with the Farr assay. Weak or absent correlations were observedbetween peptide reac-
tivities and C1q, and the Crithidia assay.
The correlation of reactivity with modifiedhistone peptides with markers for disease activity
was also determined in SLE patients with nephritis (Table 4). Anti-H4pac reactivity signifi-
cantly correlated with SLEDAI and inversely with C3 levels, while H4p did not show any signif-
icant correlation. Anti-H2Bpac and H2Bp reactivity both showed a significant correlation with
SLEDAI and a significant inverse correlation with C3 levels. In contrast, anti-H3pme and H3
reactivity did not correlate with SLEDAI or C3 levels. Reactivity with dsDNA, chromatin or
histones tested in ELISA and anti-dsDNA reactivity quantified by the Farr assay, also corre-
lated with the SLEDAI for these patients. Only anti-dsDNA and Farr showed an inverse corre-
lation with C3. Interestingly, patients who demonstrated reactivity with multiple modified
histone peptides displayed an increase of the SLEDAI and a decrease in C3 levels (Fig 4a). No
significant correlation of anti- H2pac and anti-H4pac reactivity with standard parameters for
renal functionwere found, although a trend towards a higher incidence of sustained doubling
of creatinine, or relapse in H2Bpac-high patients could be observed (S1 Table, see Additional
file 1.pdf).Time courses of plasma’s from SLE patients covering pre-flare, the flare and the
post-flare periods are rather unique. However, in 11 patients who experienced a disease flare
after initial treatment, and of whom 4 representative patients (S2 Table, see Additional file 2.
pdf)are shown in Fig 4b, a higher reactivity with H4pac could be demonstrated, followed, or
sometimes even preceded, an increase in SLEDAI and/or anti-dsDNA reactivity. No
Table 3. Correlation coefficients between reactivity with modified and unmodified histone peptides, and other serological assays in patients
with lupus nephritis.
Assay1 H4p ac H4p H2Bp ac H2Bp H3p me H3p
p p p p p p
H4pac - - - - - - - - - - - -
H4p 0.75 <0.001 - - - - - - - - - -
H2Bpac 0.54 <0.001 0.46 0.02 - - - - - - - -
H2Bp 0.49 <0.001 0.38 0.03 0.94 <0.001 - - - - - -
H3pme 0.58 <0.001 0.53 <0.001 0.38 0.01 0.35 <0.001 - - - -
H3p 0.42 0.001 0.38 0.024 0.52 0.01 0.55 <0.001 0.48 0.001 - -
dsDNA 0.50 <0.001 0.34 0.007 0.60 <0.001 0.59 <0.001 0.27 0.036 0.42 0.001
Chromatin 0.34 0.007 0.22 0.091 0.40 0.001 0.40 0.002 0.10 0.430 0.28 0.078
Histone 0.25 0.055 0.14 0.273 0.44 <0.001 0.52 <0.001 0.18 0.076 0.38 0.011
C1q 0.20 0.120 0.20 0.121 0.13 0.318 0.13 0.337 0.21 0.111 0.13 0.313
Farr 0.23 0.101 0.21 0.140 0.44 0.001 0.41 0.002 0.18 0.208 0.38 0.006
Crithidia 0.10 0.470 0.14 0.277 0.27 0.290 0.29 0.038 0.08 0.540 0.25 0.056
1H4p, histone H4 peptide; H4pac, histone H4 peptide acetylated at lysine 8, 12 and 16; H2Bp, histone H2B peptide; H2Bpac, histone H2B peptide acetylated
at lysine 12; H3p, histone H3 peptide; H3pme, histone H3 peptide trimethylated at lysine 27
doi:10.1371/journal.pone.0165373.t003
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correlation of reactivity with the respectivemodifiedhistone peptide with a specific disease
manifestation during the flare was observed.
Discussion
Our study revealed a strong reactivity with multiple modifiedhistone peptides in the majority
of SLE patients with a sensitivity of ~90% for H4pac, and a specificity>90% for H4pac, and
H2Bpac. The reactivity with H4p/H4pac and H2Bp/H2Bpac observed in this study was similar
to previous results obtained in much smaller cohorts of controls and SLE patients [8–9]. In the
majority of the SLE patients, the reactivity with the modified peptides was increased by 25–
100% compared to the unmodifiedpeptide. Reactivity with H3pme showed a high sensitivity,
but demonstrated no specificity for patients with SLE. The unexpected lack of specificity for
anti-H3p/H3pme reactivity in our assay might be due to a decreased accessibility within the cir-
culating nucleosome/apoptotic microparticle, for which we found evidence in a previous study
[6]. Another explanation might be the reactivity against methylated residues in plasmas from
healthy individuals, which has been described before for IgM [32]. Importantly, we demon-
strated that the modifiedpeptides H4pac and H2Bpac show an increased specificity and sensi-
tivity compared to their unmodified counterpart. In addition, a higher correlation with disease
activity, before treatment and during disease flares, was observed for H4pac and H2Bpac. There-
fore, these modified peptides appear to have a higher diagnostic value compared to their
unmodified counterparts.We have recently shown that circulating histones and apoptotic
microparticles, and in vitro generated NETs from SLE patients contain aforementioned histone
modifications, and that these modified histones, apoptotic microparticles and NETs are very
potent to stimulate the immune system [6,8,11]. Aforementioned histone modifications also
occur in non-apoptotic cells, but in much lower amounts [8–11]. Consequently non-apoptotic
cell-derived chromatin or microparticles have a significant lower immunostimulatory capacity,
as we previously have shown [6,8,11]. Moreover, others have used a large screen of different
modified and unmodifiedhistone peptides, and identified our original panel of histone modifi-
cations among the most prominent targets for autoantibodies in SLE patients [24,25].
Table 4. Correlation coefficients between reactivity with modified and unmodified histone peptides, dsDNA, chromatin or histones, and disease
activity (SLEDAI) or complement C3 levels in SLE patients with lupus nephritis.
Assay1 SLEDAI C3
p p
H4pac 0.42 0.01 -0.29 0.023
H4p 0.25 0.056 -0.11 0.390
H2Bpac 0.45 <0.0001 -0.37 0.003
H2Bp 0.44 0.002 -0.37 0.003
H3pme 0.25 0.055 0.08 0.547
H3p 0.14 0.304 -0.22 0.091
dsDNA 0.42 <0.0001 -0.41 <0.0001
Chromatin 0.29 <0.0001 -0.23 <0.0001
Histone 0.36 <0.0001 -0.24 <0.0001
Farr 0.26 <0.0001 -0.31 <0.0001
Crithidia 0.01 <0.0001 -0.19 <0.0001
1H4p, histone H4 peptide; H4pac, histone H4 peptide acetylated at lysine 8, 12 and 16; H2Bp, histone H2B peptide; H2Bpac, histone H2B peptide acetylated
at lysine 12; H3p, histone H3 peptide; H3pme, histone H3 peptide trimethylated at lysine 27
doi:10.1371/journal.pone.0165373.t004
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Fig 4. Reactivity with (multiple) modified peptides is associated with increased SLEDAI and follow disease activity
during disease flares. (A) SLE patients with nephritis were sorted into groups depending on the number of different modified
histone peptides they show reactivity with, and the mean SLEDAI and C3 levels were compared between these groups. (B)
Examples of reactivity with H4pac and H4p along with the SLEDAI score and anti-dsDNA reactivity in 4 patients that
experienced a disease flare after initial treatment. Patient characteristics are detailed in S1 Table. H4p, histone H4 peptide;
H4pac, histone H4 peptide acetylated at lysine 8, 12 and 16; H2Bp, histone H2B peptide; H2Bpac, histone H2B peptide
acetylated at lysine 12; H3p, histone H3 peptide; H3pme, histone H3 peptide trimethylated at lysine 27
doi:10.1371/journal.pone.0165373.g004
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Therefore, our results also confirm the important underlying role of cell death-modifiedhis-
tones in the development of SLE.
Reactivity with all (modified) histone peptides that were tested showed a significant correla-
tion with anti-dsDNA reactivity. However, anti-H3pme/H3p reactivity did not correlate with
anti-chromatin, while anti-H4pac/H4p and anti-H3pme reactivity did not correlate with overall
anti-histone reactivity. Importantly, chromatin and histones used in the respective assays were
isolated from calf thymus, which contains only a low amount of apoptotic cells and therefore, a
relatively low amount of the (apoptosis- and NETosis-associated) histone modifications.
Indeed, in our hands calf thymus-derived chromatin and histones show reactivity with mono-
clonal antibodies directed against modifiedhistones, but this reactivity is much lower com-
pared to histones/chromatin derived from apoptotic cells. In addition, non-apoptotic histone
possess other modifications in the same regions, which might interfere with the binding of the
autoantibodies we measure in our anti-peptide assays Therefore, the difference in the type and
amount of histone modifications can explain the lack of correlation that we found between the
reactivity with the panel of modified and unmodifiedhistone peptides, and non-apoptotic
chromatin and histones. We previously observed a sensitivity of 81% for anti-chromatin and
96% for anti-dsDNA in the same cohort of SLE patients with nephritis [29]. Other studies
reported different sensitivities and specificities for anti-chromatin (ranging from 45–100% and
88–100%, respectively), and for anti-dsDNA assays (ranging from 35–74% and 79–100%,
respectively) [2, 33–35]. The specificity of anti-histone autoantibodies for SLE is still under
debate, and the observedprevalence (<50%) in SLE patients is always lower compared to anti-
dsDNA and anti-chromatin reactivity [36,37], as we have previously described [29]. As out-
lined above, the large variation in sensitivity and specificity found in different studies can likely
be explained by differences in the source and methodology for the isolation of chromatin or
histones [2, 23]. Remarkably, we found no correlation for H4pac/H4p and H3pme with the
Crithidia and Farr assays, and for H3p with Crithidia assay. Note that previously, we also did
not observe a correlation of anti-histone antibodies with Farr or Crithidia [29]. Altogether, we
suggest that using apoptosis modifiedhistone peptides offer a reliable alternative with compati-
ble sensitivity and specificity, as these peptides represent the original autoantigen, i.e. apoptotic
chromatin, more accurately.
Anti-dsDNA and anti-chromatin reactivity have regularly been associated with disease
activity and the occurrence of flares in SLE patients [2, 38–41]. Here, we demonstrate that reac-
tivity with H4pac and H2Bpac correlated highly with an increased SLEDAI score and decreased
levels of C3, and followed disease activity and anti-dsDNA reactivity during flares in some
selected cases we could evaluate. Additionally, an increased SLEDAI was observed in patients
reacting with multiple modifiedpeptides. Patients with a high reactivity with these modified
peptides also appeared to have an increased number of flares or relapses. Therefore, our results
suggest that anti-H4pac and anti-H2Bpac reactivity reflects disease activity.
SLE can manifest in multiple organs, including the skin, kidneys, and brain. Therefore, diag-
nostic markers that relate to the involvement of specific organs could be helpful. We here
observeddistinct differences in anti-peptide reactivity in SLE patients with nephritis as com-
pared to patients without nephritis. In particular, the ratio of reactivity betweenmodified and
unmodifiedpeptide was higher for H2Bpac in patients with renal involvement. Differences in
anti-histone reactivity have occasionally been associated with particular diseasemanifestations
in SLE patients, including neuropsychiatric lupus [37], discoid lupus [42], and incomplete
lupus syndromes [43]. Furthermore, anti-chromatin, anti-dsDNA, and anti-histone reactivity
are unequivocally correlated to renal involvement [43], while simultaneous positivity for all
threemarkers has been suggested as a possible marker for severe lupus nephritis [44]. However,
although anti-chromatin and anti-histone reactivity are related to renal involvement,
Reactivity against Modified Histone Peptides in SLE
PLOS ONE | DOI:10.1371/journal.pone.0165373 October 25, 2016 12 / 16
measuring these reactivities using conventional chromatin or histones as substrates, is not con-
sidered to be useful to differentiate SLE with nephritis from SLE without nephritis [45].
Recently, an important role for anti-H2B autoantibodies, and plasma cells producing them, in
renal inflammation was reported in the murine NZBWF1 lupus model, although no modified
H2B peptides were tested [46]. We found significantly higher anti-H2Bpac reactivity in SLE
patients with renal involvement.
In conclusion, autoantibodies against modified histone peptides H2Bpac and H4pac are spe-
cific and highly sensitive for SLE patients with lupus nephritis, and correlate with disease activ-
ity. Our results emphasize the central role of cell death-associated histone modifications in
development of an anti-chromatin autoimmune response in SLE patients that we and others
have proposed [4,8–10, 24–25, 47–49]. Obviously, for future application of cell death-associ-
ated histone peptides in diagnostic tests, our results would need confirmation by other labs
using additional patient and control cohorts.
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